Clinical Trial Update: Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 1/2 safety and efficacy study of CYT387 in primary myelofibrosis and myelofibrosis following polycythemia vera or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• CYT387 (momelotinib) (momelotinib)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 1, Phase 2 | Status: COMPLETED